IL-CG-LIFE
5.1.2023 14:01:43 CET | Business Wire | Press release
CG Life, an integrated digital marketing and public relations agency supporting life science and healthcare companies, and MC Services AG, a major European public relations and investor relations firm with a similar life sciences focus, announced today a strategic partnership between the agencies. The two companies have created an integrated service platform for biotech and pharmaceutical companies to extend their reach and access more easily to capital, talent, and business audiences on both sides of the Atlantic. Both firms will remain fully and legally independent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005125/en/
For MC Services, this partnership provides an industry-respected gateway for accessing marketing, branding, digital marketing, public relations, and advertising capabilities in the U.S. And as CG Life’s clients increasingly request global capabilities across PR, branding, paid media, and more, CG Life will be able to activate a highly experienced communications and investor relations team in Europe and in Germany, in particular—the largest European healthcare market.
“Accessing the U.S. market is vital for the European biopharma sector, and we have worked for many years to better connect our clients to the life science ecosystem in the States,” said Raimund Gabriel, Managing Partner of MC Services. “We are excited to continue that mission by establishing a strategic alliance with CG Life, a like-minded agency in the U.S. with a global view that is equally committed to quality and performance.”
“Through extensive discussion, analysis, and reflection, both agency teams recognized that we share very similar cultural values, commitment to our clients and science, and an emphasis on providing business solutions rather than just delivering services,” said CG Life Managing Partner Erik Clausen. “We couldn’t be happier that we found a partner in MC Services that has the experience, skill and mindset, and relationships to collaborate with us and our clients.”
About MC Services AG
MC Services AG is an international public relations and investor relations firm specializing in communications for the life sciences and healthcare sectors. A strong team of science, finance, media, and communication experts, with extensive industry experience, positions MC Services as a leading life sciences agency in Europe.
MC Services' long-standing clients include international public and private companies, as well as venture capitalists and investment firms. Established for many years as a link between the healthcare industry and the financial markets, MC Services provides comprehensive services in investor relations, public relations, and financial transactions. MC Services is based in Munich, Düsseldorf, Berlin, London, and Boston. www.mc-services.eu
About CG Life
Propelled by science since 2003, CG Life’s mission is to celebrate scientific discoveries and medical innovations through personal and impactful brand experiences. The team integrates smart strategies, inspirational creativity, insightful content, clever communications, and digital platforms to create and elevate leading and disruptive science and healthcare brands. CG Life supports emerging science and technology organizations through The Market Element, a CG Life Agency. Connect with CG Life on LinkedIn, Twitter, Instagram or Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005125/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom